OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
OBSRV56

Observe Medical ASA

Medical Equipment, Supplies & DistributionVerified

Observe Medical operates with a capital structure that includes a debt-to-equity ratio of 1.03, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.48, suggesting that its current liabilities significantly exceed its current assets. This is further supported by a negative net cash position after subtracting total debt, which raises concerns about the company's ability to meet short-term obligations without external financing. In terms of profitability, Observe Medical reported a net loss of NOK 48.64 million for the period, with an operating loss of NOK 79.07 million. The return on equity (ROE) is -1.62, and the return on assets (ROA) is -0.48, both of which are negative and indicate poor performance relative to industry norms. The company's gross profit margin is 25.0%, which is below the median for its industry, suggesting inefficiencies in cost management or pricing power. The company's revenue is concentrated in a single business segment focused on medical devices for wound care and tissue repair. There is no disclosed geographic diversification, and the company's financial data does not provide a breakdown of revenue by region. This lack of geographic segmentation increases the risk of over-reliance on a single market or regulatory environment. Observe Medical's growth trajectory is currently negative, with a significant operating and net loss. The company's free cash flow is negative at NOK -36.46 million, and its operating cash flow is also negative at NOK -24.83 million. These figures suggest that the company is not generating sufficient cash from operations to sustain or grow its business without external funding. The capital expenditure of NOK -1.14 million indicates minimal investment in long-term assets, which may limit future growth potential. The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a medium liquidity risk, primarily due to the negative net cash position after subtracting total debt. The dilution risk is currently low, but the company's reliance on external financing could increase this risk in the future. No dilution sources are explicitly identified in the provided data, but the company's financial position suggests that it may need to raise additional capital, which could involve issuing new shares. Recent events and filings do not provide specific details about the company's strategic initiatives or operational changes. The company's financial performance and liquidity position suggest that it may be under pressure to improve its financial health. The absence of positive cash flow and the significant operating loss indicate that the company is in a challenging financial position and may need to implement cost-cutting measures or seek additional financing to continue operations.

30-day price · OBSRV+0.04 (+3.8%)
Low$0.96High$1.23Close$1.09As of17 May, 00:00 UTC
Profile
CompanyObserve Medical ASA
TickerOBSRV.OL
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Observe Medical ASA develops and commercializes medical devices for the treatment of chronic wounds and other tissue repair applications, primarily generating revenue through product sales to healthcare providers and institutions.

Classification. Observe Medical is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92 based on verified market data.

Observe Medical operates with a capital structure that includes a debt-to-equity ratio of 1.03, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.48, suggesting that its current liabilities significantly exceed its current assets. This is further supported by a negative net cash position after subtracting total debt, which raises concerns about the company's ability to meet short-term obligations without external financing. In terms of profitability, Observe Medical reported a net loss of NOK 48.64 million for the period, with an operating loss of NOK 79.07 million. The return on equity (ROE) is -1.62, and the return on assets (ROA) is -0.48, both of which are negative and indicate poor performance relative to industry norms. The company's gross profit margin is 25.0%, which is below the median for its industry, suggesting inefficiencies in cost management or pricing power. The company's revenue is concentrated in a single business segment focused on medical devices for wound care and tissue repair. There is no disclosed geographic diversification, and the company's financial data does not provide a breakdown of revenue by region. This lack of geographic segmentation increases the risk of over-reliance on a single market or regulatory environment. Observe Medical's growth trajectory is currently negative, with a significant operating and net loss. The company's free cash flow is negative at NOK -36.46 million, and its operating cash flow is also negative at NOK -24.83 million. These figures suggest that the company is not generating sufficient cash from operations to sustain or grow its business without external funding. The capital expenditure of NOK -1.14 million indicates minimal investment in long-term assets, which may limit future growth potential. The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a medium liquidity risk, primarily due to the negative net cash position after subtracting total debt. The dilution risk is currently low, but the company's reliance on external financing could increase this risk in the future. No dilution sources are explicitly identified in the provided data, but the company's financial position suggests that it may need to raise additional capital, which could involve issuing new shares. Recent events and filings do not provide specific details about the company's strategic initiatives or operational changes. The company's financial performance and liquidity position suggest that it may be under pressure to improve its financial health. The absence of positive cash flow and the significant operating loss indicate that the company is in a challenging financial position and may need to implement cost-cutting measures or seek additional financing to continue operations.
Key takeaways
  • Observe Medical is experiencing significant financial losses, with a net loss of NOK 48.64 million and an operating loss of NOK 79.07 million.
  • The company's liquidity position is weak, as indicated by a current ratio of 0.48 and a negative net cash position after subtracting total debt.
  • The company's profitability metrics, including ROE and ROA, are negative, indicating poor performance relative to industry standards.
  • Observe Medical's revenue is concentrated in a single business segment, and there is no geographic diversification disclosed, increasing operational risk.
  • The company's free cash flow and operating cash flow are both negative, suggesting a need for external financing to sustain operations.
  • The company's capital expenditure is minimal, which may limit future growth potential.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyNOK
Revenue$18.8M
Gross profit$4.7M
Operating income-$79.1M
Net income-$48.6M
R&D
SG&A
D&A
SBC
Operating cash flow-$24.8M
CapEx-$1.1M
Free cash flow-$36.5M
Total assets$101.2M
Total liabilities$71.2M
Total equity$30.0M
Cash & equivalents$11.5M
Long-term debt$30.7M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$30.0M
Net cash-$19.2M
Current ratio0.5
Debt/Equity1.0
ROA-48.1%
ROE-1.6%
Cash conversion51.0%
CapEx/Revenue-6.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricOBSRVActivity
Op margin-420.3%3.9% medp25 -31.3% · p75 14.4%bottom quartile
Net margin-258.6%2.4% medp25 -30.5% · p75 11.1%bottom quartile
Gross margin25.0%46.7% medp25 28.2% · p75 63.1%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-6.0%-4.8% medp25 -11.6% · p75 -2.4%below median
Debt / equity103.0%17.9% medp25 2.7% · p75 52.2%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 23:20 UTC#347e068b
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 20:01 UTCJob: 6d8b0b38